Literature DB >> 1723442

Developmental profile of patients with maple syrup urine disease.

A Nord1, W J van Doorninck, C Greene.   

Abstract

The progress of nine maple syrup urine disease patients (eight classical, one possible variant) was reviewed to look for similarities in developmental patterns. A consistent developmental profile of stronger Verbal than Performance IQ and lower than familially expected IQ was seen. Younger age at diagnosis was associated with a milder neonatal course. Those who were asymptomatic or suffered mild complications in the newborn period have higher IQs than children experiencing moderate or severe complications. Children with asymptomatic or mild neonatal course also required less special education services. Overall, a picture of ubiquitous motor, visual-analytic and learning deficits is seen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723442     DOI: 10.1007/bf01800467

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

1.  MAPLE SYRUP URINE DISEASE, WITH PARTICULAR REFERENCE TO DIETOTHERAPY.

Authors:  S E SNYDERMAN; P M NORTON; E ROITMAN; L E HOLT
Journal:  Pediatrics       Date:  1964-10       Impact factor: 7.124

2.  Maple syrup urine disease; an inborn error of the metabolism of valine, leucine, and isoleucine associated with gross mental deficiency.

Authors:  D Y MACKENZIE; L I WOOLF
Journal:  Br Med J       Date:  1959-01-10

3.  Maple syrup urine disease.

Authors:  J DANCIS; M LEVITZ; S MILLER; R G WESTALL
Journal:  Br Med J       Date:  1959-01-10

4.  Maple syrup disease; isolation and identification of organic acids in the urine.

Authors:  J H MENKES
Journal:  Pediatrics       Date:  1959-02       Impact factor: 7.124

5.  A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance.

Authors:  J H MENKES; P L HURST; J M CRAIG
Journal:  Pediatrics       Date:  1954-11       Impact factor: 7.124

6.  M aple syrup urine disease. A review with a report of an additional case.

Authors:  J F Schwartz; E T Kolendrianos
Journal:  Dev Med Child Neurol       Date:  1969-08       Impact factor: 5.449

7.  The treatment of maple syrup urine disease.

Authors:  S I Goodman; S Pollak; B Miles; D O'Brien
Journal:  J Pediatr       Date:  1969-09       Impact factor: 4.406

8.  Management of maple syrup urine disease in Canada. Committee for improvement of Hereditary Disease Management.

Authors: 
Journal:  Can Med Assoc J       Date:  1976-11-20       Impact factor: 8.262

9.  The therapy of maple syrup urine disease.

Authors:  S E Snyderman
Journal:  Am J Dis Child       Date:  1967-01

10.  Outcome of early and long-term management of classical maple syrup urine disease.

Authors:  C L Clow; T M Reade; C R Scriver
Journal:  Pediatrics       Date:  1981-12       Impact factor: 7.124

View more
  9 in total

1.  Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Patrícia Fernanda Schuck; André Quincozes Dos Santos; Maria Caroline Jacques-Silva; Carmem Gottfried; Regina Pessoa-Pureur; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

2.  The longest-surviving patient with classical maple syrup urine disease.

Authors:  Carel le Roux; Elaine Murphy; Maggie Lilburn; Philip J Lee
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Neurocognitive phenotype of isolated methylmalonic acidemia.

Authors:  Colin J O'Shea; Jennifer L Sloan; Edythe A Wiggs; Maryland Pao; Andrea Gropman; Eva H Baker; Irini Manoli; Charles P Venditti; Joseph Snow
Journal:  Pediatrics       Date:  2012-05-21       Impact factor: 7.124

4.  Neurocognitive profiles in MSUD school-age patients.

Authors:  Juliette Bouchereau; Julie Leduc-Leballeur; Samia Pichard; Apolline Imbard; Jean-François Benoist; Marie-Thérèse Abi Warde; Jean-Baptiste Arnoux; Valérie Barbier; Anaïs Brassier; Pierre Broué; Aline Cano; Brigitte Chabrol; Gilles Damon; Claire Gay; Isabelle Guillain; Florence Habarou; Delphine Lamireau; Chris Ottolenghi; Laetitia Paermentier; Frédérique Sabourdy; Guy Touati; Hélène Ogier de Baulny; Pascale de Lonlay; Manuel Schiff
Journal:  J Inherit Metab Dis       Date:  2017-03-21       Impact factor: 4.982

5.  Neuropsychometric outcome predictors for adults with maple syrup urine disease.

Authors:  C le Roux; E Murphy; P Hallam; M Lilburn; D Orlowska; P Lee
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

6.  Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series.

Authors:  D A Shellmer; A DeVito Dabbs; M A Dew; R B Noll; H Feldman; K A Strauss; D H Morton; J Vockley; G V Mazariegos
Journal:  Pediatr Transplant       Date:  2010-10-08

7.  Young adults with MSUD and their transition to adulthood: psychosocial issues.

Authors:  Wendy Packman; Indira Mehta; Samantha Rafie; Jayanthi Mehta; Mariana Naldi; Kim Hart Mooney
Journal:  J Genet Couns       Date:  2012-02-17       Impact factor: 2.537

8.  Reduction of glutamate uptake into cerebral cortex of developing rats by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Aline Meyer Rosa; Moacir Wajner; Susana Wofchuk; Regina Pessoa Pureur
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

9.  Psychosocial issues in families affected by maple syrup urine disease.

Authors:  Wendy Packman; Shelly L Henderson; Indira Mehta; Rama Ronen; Dean Danner; Beth Chesterman; Seymour Packman
Journal:  J Genet Couns       Date:  2007-08-17       Impact factor: 2.537

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.